Thymidine conjugate |
vinblastine-thymidine (Covalent Bond) |
Molecular level |
K562, HT29, and MCF7 cell lines |
[19] |
Folic acid and folate |
desacetylvinblastine monohydrazide attached to a hydrophilic folic acid-peptide compound(EC145) (Covalent Bond) |
Molecular level |
novel synthesis study and the clinical pharmacokinetics and exposure-toxicity relationship study |
[77, 79] |
vinblastine-folate by carbohydrate-based synthetic approach(EC0905) (Covalent Bond) |
Molecular level |
novel synthesis study and invasive urothelial carcinoma in dogs |
[80-82] |
vinblastine sulfate-loaded folate-conjugated bovine serumalbumin nanoparticles |
~150 nm |
novel synthesis study |
[83] |
PLGA |
vinblastine encapsulated in PLGA microspheres |
46 μm |
pharmacokinetics study |
[84] |
Liposome |
anti-HER2 immunoliposomal vinblastine |
99.5 nm |
SKBR-3 and BT474-M2 in vitro and BT474-M2 xenografts in mice |
[85] |
magnetic cationic liposomes packaged vinblastine |
105-267 nm |
B16-F10 in vitro and in mice |
[74, 78] |
anionic liposomes (DPPC and DPPG with cholesterol) |
- |
six cell lines tested |
[86] |
new liposome formulations (wheat germ lipids) |
- |
against nine human leukemic cell lines |
[87] |
multi-lamellar vesicle-liposomes |
- |
UV-2237M murine fibrosarcoma and its Adriamycin (ADR)-selected multidrug resistant (MDR) variants. |
[88] |